The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Amid steady expectations in the clinical contract research sector, Fortrea reiterated its fiscal year 2026 guidance, targeting revenues between $2.55B and $2.65B, versus the analyst consensus estimate of $2.594B, according to Benzinga reports. The company also targets adjusted EBITDA in the range of $190M to $220M, reflecting confidence in its operational plan with no change from prior guidance.
The reiteration comes as the clinical research organization (CRO) sector faces demand pressure from cautious pharmaceutical spending. According to market data, shares of peers IQVIA Holdings and ICON PLC saw modest moves in recent sessions, with investors focused on new order growth. Fortrea's stable guidance may be viewed relatively positively in an uncertain environment.
Sign in to access this content
Sign InNo current stock price levels were provided by the company, but investors may watch for any signals on order growth in the second half of the year. No major economic events this week directly impact the sector, though Fed officials' speeches could provide broader interest-rate signals that affect biotech financing costs.